FDA warns of test inaccuracies, IHS finds 'acceptable'
The Associated Press
WASHINGTON — The head of the Food and Drug Administration said Friday his agency has provided new guidance to the White House after data suggested that a rapid COVID-19 test used by President Donald Trump and others every day may provide inaccuracies and false negatives.
Commissioner Steve Hahn said that if a person is suspected of having the disease caused by the coronavirus, "it might be worth, if the test is negative, getting a second confirmatory test. That's what our guidance is about."
The test, by Abbott Laboratories, is used daily at the White House to test Trump and key members of his staff, including the coronavirus task force. The FDA said late Thursday it was investigating preliminary data suggesting the 15-minute test can miss COVID-19 cases, falsely clearing infected patients.
Hahn, asked on CBS on Friday whether he'd continue to recommend using the test at the White House, said, "That will be a White House decision." But he said the test is on the market and the FDA continues to "recommend its use or to have it available for use."
Federal health officials have been alerting doctors to the potential inaccuracy in the test, which is used at thousands of hospitals, clinics and testing sites across the United States.
In the beginning of April, Dr. Deborah Birx, coronavirus response coordinator for the White House said IHS was going to get these 15-minute tests.
“So what we're seeing finally is testing improving, more testing being done,” Dr Birx said. “Still a high level of negative in states without hotspots, allowing them to do more of this surveillance and containment, and then prioritizing this new rapid test kit to those areas that may not have the same amount of access to the Indian Health Services, and to the public health institutions and the public health in state labs, so that they can use that and start forward leaning into surveillance.”
IHS received 250 Abbott ID NOW testing machines and 90,000 tests from the White House, said IHS officials during a media call Thursday. IHS distributed these machines to direct-service and tribally-run health facilities across the country in April.
IHS found the machines to be "acceptable for patient testing," according to a study by the Gallup Indian Medical Center. It tested at 98.9 percent accuracy compared to another analyzer.
Clinics in the Indian health system that received the analyzer machine have received a technical brief from Abbott Laboratories, said IHS spokesperson Joshua Marshall in an email.
Marshall said the brief indicates: "Negative results should be treated as presumptive and, if inconsistent with clinical signs and symptoms or necessary for patient management, should be tested with an alternative molecular assay. Negative results do not preclude SARS-CoV-2 infection and should not be used as the sole basis for patient management decisions. Negative results should be considered in the context of a patient's recent exposures, history, presence of clinical signs and symptoms consistent with COVID-19."
(Related: 'We're finally seeing more testing')
The FDA warning came a day after researchers at New York University reported results suggesting Abbott's test can miss up to half the infections caught by a rival test made by Cepheid. The research has not been peer-reviewed or published in a medical journal and was based on about 100 patients.
The researchers found that Abbott's test, run on the company's portable ID NOW system, missed one-third of the infections caught by Cepheid's test when swabs were stored in liquid used to transport laboratory samples. When the samples were kept dry the test missed 48 percent of the cases flagged by Cepheid's test.
The researchers called the test's performance "unacceptable," due to the risk of falsely clearing patients who could spread the infection to others. They acknowledged shortcomings of the study, including the time needed to transport patient samples to the device for processing.
Abbott rejected the findings, saying the researchers used the test "in ways that it was not designed to be used."
"ID NOW is intended to be used near the patient with a direct swab test method," the company said in a statement.
The company pointed to other independent study results that found the test accurately detected 90 percent or more infections.
Last month Abbott changed the instructions for its test to explicitly warn against putting patient samples in transport chemicals. The update came after researchers at the Cleveland Clinic reported a 15 percent false negative rate for samples stored in the chemicals.
The FDA said it was reviewing the data with Abbott and was working on a letter to health care providers about potential accuracy issues. The agency said physicians may need to confirm the results of a negative Abbott test if patients have signs and symptoms of the virus. Regulators said they are requiring Abbott to conduct follow-up studies on the test's accuracy.
The FDA first cleared Abbott's test in late March under emergency powers used to quickly accelerate the review of tests and treatments during a public health crisis. The agency has authorized more than 90 tests, effectively flooding the market with testing options amid persistent problems ramping up testing levels.
For weeks, Trump has promoted Abbott's test as a "game changer." On Monday, the company's ID NOW system and test cartridges were displayed prominently at a Rose Garden press conference meant to highlight the nation's progress on testing.
"These tests are highly sophisticated — very quick, very good," Trump told reporters.
The administration has shipped more than 235,000 of the tests to state public health laboratories. And Abbott has separately said it has distributed 1.8 million tests to health care facilities in all 50 states.
A White House spokesperson did not immediately respond to a request for comment Thursday night.
Indian Country Today contributed to this report.